These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 20308371

  • 1. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
    Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL.
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2638-45. PubMed ID: 20308371
    [Abstract] [Full Text] [Related]

  • 2. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y, Kobayashi Y.
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [Abstract] [Full Text] [Related]

  • 3. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E, Cabot G, Mulet X, García-Castillo M, del Campo R, Juan C, Cantón R, Oliver A.
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [Abstract] [Full Text] [Related]

  • 4. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA, Nicolau DP.
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [Abstract] [Full Text] [Related]

  • 5. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF, Liu CP, Wang NY, Shih SC.
    BMC Infect Dis; 2016 Aug 24; 16(1):444. PubMed ID: 27553962
    [Abstract] [Full Text] [Related]

  • 6. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.
    Firsov AA, Gilbert D, Greer K, Portnoy YA, Zinner SH.
    Antimicrob Agents Chemother; 2012 Mar 24; 56(3):1223-8. PubMed ID: 22203591
    [Abstract] [Full Text] [Related]

  • 7. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.
    Kim A, Banevicius MA, Nicolau DP.
    Antimicrob Agents Chemother; 2008 Jul 24; 52(7):2497-502. PubMed ID: 18458125
    [Abstract] [Full Text] [Related]

  • 8. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
    Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R, Drusano GL.
    Antimicrob Agents Chemother; 2010 Jun 24; 54(6):2646-54. PubMed ID: 20368395
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
    Bretonnière C, Jacqueline C, Caillon J, Guitton C, Le Mabecque V, Miégeville AF, Villers D, Potel G, Boutoille D.
    J Antimicrob Chemother; 2010 Nov 24; 65(11):2423-7. PubMed ID: 20858688
    [Abstract] [Full Text] [Related]

  • 10. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
    Eagye KJ, Banevicius MA, Nicolau DP.
    Crit Care Med; 2012 Apr 24; 40(4):1329-32. PubMed ID: 22425824
    [Abstract] [Full Text] [Related]

  • 11. Mutant prevention concentrations of four carbapenems against gram-negative rods.
    Credito K, Kosowska-Shick K, Appelbaum PC.
    Antimicrob Agents Chemother; 2010 Jun 24; 54(6):2692-5. PubMed ID: 20308376
    [Abstract] [Full Text] [Related]

  • 12. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S, Ge Y, Livermore DM.
    Antimicrob Agents Chemother; 2004 Aug 24; 48(8):3086-92. PubMed ID: 15273124
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.
    Bowker KE, Noel AR, Tomaselli SG, Elliott H, Macgowan AP.
    Antimicrob Agents Chemother; 2012 Oct 24; 56(10):5009-15. PubMed ID: 22713338
    [Abstract] [Full Text] [Related]

  • 14. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
    Crandon JL, Bulik CC, Nicolau DP.
    Antimicrob Agents Chemother; 2009 Oct 24; 53(10):4352-6. PubMed ID: 19770286
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA, Marie Queenan A, Morrow BJ, Shang W, Amsler K, He W, Lynch AS, Pillar C, Flamm RK.
    J Antimicrob Chemother; 2011 Oct 24; 66(10):2298-307. PubMed ID: 21775338
    [Abstract] [Full Text] [Related]

  • 16. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
    Kiratisin P, Keel RA, Nicolau DP.
    Int J Antimicrob Agents; 2013 Jan 24; 41(1):47-51. PubMed ID: 23127484
    [Abstract] [Full Text] [Related]

  • 17. Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.
    Betriu C, Gómez M, López-Fabal F, Culebras E, Rodríguez-Avial I, Picazo JJ.
    Eur J Clin Microbiol Infect Dis; 2010 Sep 24; 29(9):1179-81. PubMed ID: 20521156
    [Abstract] [Full Text] [Related]

  • 18. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV, Briceno DF, Ruiz SJ, Furtado GH, Nicolau DP.
    Braz J Infect Dis; 2011 Sep 24; 15(5):413-9. PubMed ID: 22230846
    [Abstract] [Full Text] [Related]

  • 19. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.
    Drusano GL, Bonomo RA, Bahniuk N, Bulitta JB, Vanscoy B, Defiglio H, Fikes S, Brown D, Drawz SM, Kulawy R, Louie A.
    Antimicrob Agents Chemother; 2012 Jan 24; 56(1):231-42. PubMed ID: 22005996
    [Abstract] [Full Text] [Related]

  • 20. lptG contributes to changes in membrane permeability and the emergence of multidrug hypersusceptibility in a cystic fibrosis isolate of Pseudomonas aeruginosa.
    Harrison LB, Fowler RC, Abdalhamid B, Selmecki A, Hanson ND.
    Microbiologyopen; 2019 Nov 24; 8(11):e844. PubMed ID: 30977288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.